Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.

Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ, Rasheed ZA, Mao S, Netto GJ, Sidransky D, Hoque MO.

Cancer Res. 2018 Jan 1;78(1):168-181. doi: 10.1158/0008-5472.CAN-17-0836. Epub 2017 Nov 27.

PMID:
29180467
2.

The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.

Begum A, Ewachiw T, Jung C, Huang A, Norberg KJ, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, Wood L, Wang C, Wolfgang C, DeJesus-Acosta A, Laheru D, Shapiro IM, Padval M, Pachter JA, Weaver DT, Rasheed ZA, Matsui W.

PLoS One. 2017 Jul 10;12(7):e0180181. doi: 10.1371/journal.pone.0180181. eCollection 2017.

3.

Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.

Poruk KE, Blackford AL, Weiss MJ, Cameron JL, He J, Goggins M, Rasheed ZA, Wolfgang CL, Wood LD.

Clin Cancer Res. 2017 Jun 1;23(11):2681-2690. doi: 10.1158/1078-0432.CCR-16-1467. Epub 2016 Oct 27.

PMID:
27789528
4.

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation.

Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, Christenson ES, Medford A, Mattox A, De Marzo AM, Argani P, Chawla A, Hurley PJ, Lauring J, Park BH.

Oncotarget. 2016 Feb 2;7(5):6281-93. doi: 10.18632/oncotarget.7057.

5.

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.

Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL.

Ann Surg. 2016 Dec;264(6):1073-1081.

6.

DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer.

Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A, Leach SD.

Gastroenterology. 2014 Jan;146(1):245-56. doi: 10.1053/j.gastro.2013.09.050. Epub 2013 Oct 2.

7.

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.

Cancer Lett. 2013 Jul 10;335(1):41-51. doi: 10.1016/j.canlet.2013.01.054. Epub 2013 Feb 10.

8.

Heterogeneity and targeting of pancreatic cancer stem cells.

Penchev VR, Rasheed ZA, Maitra A, Matsui W.

Clin Cancer Res. 2012 Aug 15;18(16):4277-84. doi: 10.1158/1078-0432.CCR-11-3112. Review.

9.

Pathology of pancreatic stroma in PDAC.

Rasheed ZA, Matsui W, Maitra A.

In: Grippo PJ, Munshi HG, editors. Pancreatic Cancer and Tumor Microenvironment. Trivandrum (India): Transworld Research Network; 2012. Chapter 1.

10.

The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.

Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, De Oliveira E, Zhang Q, Puig O, Matsui W, Hidalgo M, Maitra A, Rajeshkumar NV.

Mol Cancer Ther. 2012 Sep;11(9):1999-2009. doi: 10.1158/1535-7163.MCT-12-0017. Epub 2012 Jul 2.

11.

Biological and clinical relevance of stem cells in pancreatic adenocarcinoma.

Rasheed ZA, Matsui W.

J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:15-8. doi: 10.1111/j.1440-1746.2011.07015.x. Review.

12.

Concise review: Emerging concepts in clinical targeting of cancer stem cells.

Rasheed ZA, Kowalski J, Smith BD, Matsui W.

Stem Cells. 2011 Jun;29(6):883-7. doi: 10.1002/stem.648. Review.

13.

Tumor-initiating cells are rare in many human tumors.

Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV, Hidalgo M, Tsao M, Ailles L, Waddell TK, Maitra A, Neel BG, Matsui W.

Cell Stem Cell. 2010 Sep 3;7(3):279-82. doi: 10.1016/j.stem.2010.08.009.

14.

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M.

Mol Cancer Ther. 2010 Sep;9(9):2582-92. doi: 10.1158/1535-7163.MCT-10-0370. Epub 2010 Jul 26.

15.

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W.

J Natl Cancer Inst. 2010 Mar 3;102(5):340-51. doi: 10.1093/jnci/djp535. Epub 2010 Feb 17.

16.

Mechanisms of resistance to topoisomerase I-targeting drugs.

Rasheed ZA, Rubin EH.

Oncogene. 2003 Oct 20;22(47):7296-304. Review.

PMID:
14576839
17.

The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies.

Rasheed ZA, Saleem A, Ravee Y, Pandolfi PP, Rubin EH.

Exp Cell Res. 2002 Jul 15;277(2):152-60.

PMID:
12083797

Supplemental Content

Loading ...
Support Center